Agreed it is probably the right move to maintain a solid relationship.
Still think Leo has created a confusing conversation around up-listing with the PR about a shareholder meeting and BOD vote, after a PR from a year previous. I would venture to say that Leo is having the same issue I am having. How can the stock not be getting more support from recent results? Hopefully seeing the statistics is what the market is waiting on. Mentioning shorts shows some frustrated emotions.
That's good, actually great. The higher the Cellceutix price, the fewer shares Leo is required to sell. May the currently allotted Aspire shares last forever..................
Market Data 
Markets 
AI
